Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
AbbVie
Biotech
AbbVie pens $1.4B deal for deprioritized IBD drug from Nxera
AbbVie has added another angle to its relationship with Nxera, paying $100 million upfront for a phase 1 inflammatory bowel disease candidate.
James Waldron
Nov 4, 2026 7:20am
AbbVie invests £120M in UK, including expanded R&D site
Nov 4, 2026 2:31am
AbbVie drops ph. 2 solid tumor drug over ‘limited benefit’
Nov 3, 2026 8:38am
AbbVie posts phase 3 HS win but falls short of expectations
Oct 22, 2026 10:39am
AbbVie’s next-gen Crohn’s combo beats Skyrizi in ph. 2 test
Oct 19, 2026 5:15am
Genmab ph. 2 data spur claim ADC ‘clearly superior’ to Elahere
Oct 5, 2026 4:14am
